NCT02508441 - Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2015

Primary Completion Date

November 13, 2017

Study Completion Date

November 13, 2017

Conditions

Advanced Unresectable Solid Tumors

Interventions

DRUG

Andes-1537 for Injection

"Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle"

Trial Locations (1)

94115

UCSF Medical Center at Mount Zion, Helen Diller Family Comprehensive Cancer Center, Early Phase Clinical Trials, San Francisco